MCID: ACT105
MIFTS: 52

Acute Mountain Sickness

Categories: Blood diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Acute Mountain Sickness

MalaCards integrated aliases for Acute Mountain Sickness:

Name: Acute Mountain Sickness 20 70
High Altitude Pulmonary Edema 20 58 17 70
Altitude Sickness 20 17 70
High Altitude Cerebral Edema 20 70
Mountain Sickness 20 70
Altitude Anoxia 20

Characteristics:

Orphanet epidemiological data:

58
high altitude pulmonary edema
Prevalence: 1-9/1000000 (Europe);

Classifications:

Orphanet: 58  
Rare respiratory diseases


External Ids:

ICD10 via Orphanet 33 J81
UMLS via Orphanet 71 C0340100
Orphanet 58 ORPHA330012
UMLS 70 C0002351 C0238284 C0340100 more

Summaries for Acute Mountain Sickness

MalaCards based summary : Acute Mountain Sickness, also known as high altitude pulmonary edema, is related to chronic mountain sickness and hypoxia, and has symptoms including dyspnea, apnea and cheyne-stokes respiration. An important gene associated with Acute Mountain Sickness is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Pathways in cancer. The drugs Ibuprofen and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and kidney, and related phenotypes are cardiovascular system and behavior/neurological

Wikipedia : 73 Altitude sickness, the mildest form being acute mountain sickness (AMS), is the harmful effect of high... more...

Related Diseases for Acute Mountain Sickness

Diseases in the Acute Mountain Sickness family:

Chronic Mountain Sickness

Diseases related to Acute Mountain Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 286)
# Related Disease Score Top Affiliating Genes
1 chronic mountain sickness 32.4 VEGFA NOS3 EDN1
2 hypoxia 30.9 VHL VEGFA HIF1AN HIF1A EGLN1
3 pulmonary edema 30.5 PIK3C2A NOS3 HSPA1A HIF1A EDN1 AGTR1
4 patent ductus arteriosus 1 30.4 VEGFA EDN1 ACE
5 pulmonary hypertension 30.4 VEGFA NOS3 HIF1A EDN1 AGTR1 ACE
6 limb ischemia 30.3 VEGFA NOS3 HIF1A EDN1 ACE
7 sleep disorder 30.3 HIF1A EDN1 ACE
8 renal hypertension 30.3 NOS3 EDN1 AGTR1 ACE
9 migraine with or without aura 1 30.2 S100B NOS3 EDN1 CCK ADRB2 ACE
10 hyperglycemia 30.1 NOS3 HIF1A CCK AGTR1
11 lung disease 30.0 VEGFA ENO2 EDN1 ADRB2 ACE
12 hemiplegia 30.0 S100B ENO2 EDN1
13 stroke, ischemic 29.9 NOS3 MB ENO2 AGTR1 ACE
14 polycythemia 29.9 VHL VEGFA HIF1A EGLN1 EDN1 ACE
15 pericardial effusion 29.8 VEGFA PIK3C2A HIF1A ACE
16 acute kidney failure 29.8 PIK3C2A MB HSPA1A
17 congestive heart failure 29.4 VEGFA PIK3C2A NOS3 EDN1 AGTR1 ADRB2
18 diabetes mellitus 28.6 VEGFA PIK3C2A NOS3 FLT1 EDN1 CCK
19 disease of mental health 27.8 VEGFA S100B PIK3C2A NOS3 MB HIF1A
20 unilateral absence of a pulmonary artery 11.2
21 headache 10.8
22 autoimmune lymphoproliferative syndrome 10.6
23 anoxia 10.6
24 ataxia and polyneuropathy, adult-onset 10.5
25 arteritic anterior ischemic optic neuropathy 10.4 NOS3 ACE
26 hydrops, lactic acidosis, and sideroblastic anemia 10.4
27 intravascular papillary endothelial hyperplasia 10.4 VEGFA HIF1A
28 hemifacial spasm 10.4 VEGFA NOS3
29 posterior scleritis 10.4 VEGFA ACE
30 metabolic acidosis 10.4
31 47,xyy 10.4
32 fumarate hydratase deficiency 10.4 VHL HIF1A
33 meningococcal infection 10.3 AGTR1 ADRB2
34 renal artery disease 10.3 NOS3 AGTR1 ACE
35 hypertensive retinopathy 10.3 VEGFA AGTR1 ACE
36 hypertensive nephropathy 10.3 VEGFA AGTR1 ACE
37 resting heart rate, variation in 10.3
38 intracranial hypertension 10.3
39 cytokine deficiency 10.3
40 ischemic colitis 10.3 VEGFA HIF1A ACE
41 diastolic heart failure 10.3 NOS3 AGTR1 ACE
42 plantar fasciitis 10.3 VEGFA NOS3
43 raynaud disease 10.3 EDN1 AGTR1 ACE
44 pulmonary hypertension, primary, 1 10.3
45 pulmonary embolism 10.3
46 myocardial stunning 10.3 EDN1 AGTR1 ACE
47 retinal hemangioblastoma 10.3 VHL VEGFA HIF1A
48 mitral valve disease 10.3 NOS3 AGTR1 ACE
49 chronic pulmonary heart disease 10.3 NOS3 EDN1 ACE
50 malignant hypertension 10.3 EDN1 AGTR1 ACE

Graphical network of the top 20 diseases related to Acute Mountain Sickness:



Diseases related to Acute Mountain Sickness

Symptoms & Phenotypes for Acute Mountain Sickness

UMLS symptoms related to Acute Mountain Sickness:


dyspnea; apnea; cheyne-stokes respiration; coughing; hoarseness

MGI Mouse Phenotypes related to Acute Mountain Sickness:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 ACE ADRB2 AGTR1 BDKRB2 EDN1 EGLN1
2 behavior/neurological MP:0005386 10.32 ACE ADRB2 AGTR1 BDKRB2 CCK ENO2
3 cellular MP:0005384 10.29 ADRB2 BDKRB2 EGLN1 ENO2 FLT1 HIF1A
4 growth/size/body region MP:0005378 10.28 ACE ADRB2 AGTR1 EDN1 EGLN1 ENO2
5 homeostasis/metabolism MP:0005376 10.27 ACE ADRB2 AGTR1 BDKRB2 CCK EDN1
6 hematopoietic system MP:0005397 10.25 ACE ADRB2 AGTR1 BDKRB2 CCK EGLN1
7 immune system MP:0005387 10.13 ACE ADRB2 AGTR1 BDKRB2 CCK EGLN1
8 embryo MP:0005380 10.11 ACE EDN1 EGLN1 FLT1 HIF1A MB
9 muscle MP:0005369 9.96 ADRB2 EDN1 EGLN1 FLT1 HIF1A HIF1AN
10 nervous system MP:0003631 9.93 ACE ADRB2 AGTR1 CCK EDN1 EGLN1
11 normal MP:0002873 9.61 BDKRB2 EDN1 FLT1 HIF1A HIF1AN NOS3
12 renal/urinary system MP:0005367 9.36 ACE AGTR1 BDKRB2 CCK EDN1 EGLN1

Drugs & Therapeutics for Acute Mountain Sickness

Drugs for Acute Mountain Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ibuprofen Approved Phase 4 15687-27-1 3672
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
5
Nifedipine Approved Phase 4 21829-25-4 4485
6
Sodium citrate Approved, Investigational Phase 4 68-04-2
7
Methazolamide Approved Phase 4 554-57-4 4100 5353756
8
Metformin Approved Phase 4 657-24-9 14219 4091
9
Riociguat Approved Phase 4 625115-55-1
10
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
11
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
12
Cetirizine Approved Phase 4 83881-51-0 2678
13
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
14
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
15
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
16
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
17
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
18
Quercetin Experimental, Investigational Phase 4 117-39-5 5280343
19 Antirheumatic Agents Phase 4
20 Anti-Inflammatory Agents, Non-Steroidal Phase 4
21 Cyclooxygenase Inhibitors Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Analgesics Phase 4
24 Hormones Phase 4
25 Neurotransmitter Agents Phase 4
26 Gastrointestinal Agents Phase 4
27 Antiemetics Phase 4
28 Hematinics Phase 4
29 Epoetin alfa Phase 4 113427-24-0
30 Antipyretics Phase 4
31 Vasodilator Agents Phase 4
32 Phosphodiesterase Inhibitors Phase 4
33 Antihypertensive Agents Phase 4
34 Phosphodiesterase 5 Inhibitors Phase 4
35 Antineoplastic Agents, Hormonal Phase 4
36 Tocolytic Agents Phase 4
37 calcium channel blockers Phase 4
38 Calcium, Dietary Phase 4
39 Citrate Phase 4
40 Sildenafil Citrate Phase 4 171599-83-0
41 Hypoglycemic Agents Phase 4
42 Angiotensin II Type 1 Receptor Blockers Phase 4
43 Angiotensin Receptor Antagonists Phase 4
44 Giapreza Phase 4
45 Angiotensinogen Phase 4
46 Anti-Allergic Agents Phase 4
47 Histamine H1 Antagonists, Non-Sedating Phase 4
48 Histamine Antagonists Phase 4
49
Histamine Phosphate Phase 4 51-74-1 65513
50 Histamine H1 Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 Double Blind, Placebo Controlled Randomised Trial of Acetazolamide Versus Placebo in the Prevention of Acute Mountain Sickness During Rapid Ascent Completed NCT01418157 Phase 4 Acetazolamide;Placebo
2 Randomized, Controlled Trial of Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4 Erythropoietin
3 Ibuprofen vs Acetaminophen in the Prevention of Acute Mountain Sickness: A Double Blind, Randomized Controlled Trial Completed NCT02244437 Phase 4 Ibuprofen;Acetaminophen
4 Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing Completed NCT01993667 Phase 4 Low Dose Acetazolamide;Normal Dose Acetazolamide
5 Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness Completed NCT00627965 Phase 4 Sildenafil citrate;Placebo
6 Dexamethasone for Prophylaxis of Acute Mountain Sickness in Patients With Chronic Obstructive Pulmonary Disease Travelling to Altitude Completed NCT02450968 Phase 4 Dexamethasone;Placebo
7 Three New Ideas to Protect Special Forces From the Stress of High Altitude Completed NCT02463357 Phase 4 Nifedipine extended release;Methazolamide;Metformin;Placebo;Nitrite
8 The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
9 The Effect of Riociguat on Gas Exchange, Exercise Performance, and Pulmonary Artery Pressure During Acute Altitude Exposure Completed NCT02024386 Phase 4 Riociguat
10 HIGH Altitude CArdiovascular REsearch in the ANDES Completed NCT01830530 Phase 4 Telmisartan;Nifedipine;placebo
11 Hypoventilation and High Altitude Chronic Polycythemia: Acetazolamide as a Possible Treatment Completed NCT00424970 Phase 4 acetazolamide
12 Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia Completed NCT03192488 Phase 4 Cetirizine;Placebo oral capsule
13 Acetazolamide for Prevention of Acute Mountain Sickness in Healthy Lowlanders Older Than 40 Years. Randomized Trial. Active, not recruiting NCT03561675 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
14 Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03536520 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
15 Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03536507 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
16 Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03536455 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
17 Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03536429 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
18 Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03540914 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
19 Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03537924 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
20 Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03539367 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
21 A Prospective, Double-blind, Randomized, Placebo-controlled Trial of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography Terminated NCT03490916 Phase 4 Acetazolamide;Placebo
22 Modulation of Oxygen Sensor Reactivity to Mimic Altitude Acclimatization Terminated NCT01241513 Phase 4 NAC;Placebo
23 A Randomized Controlled Trial of Altitude Sickness Prevention and Efficacy of Comparative Treatments Completed NCT02604173 Phase 3 Budesonide;Acetazolamide;Placebo
24 Randomized Double-Blind Placebo-Controlled Trial of Oral Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness. Completed NCT00664001 Phase 3
25 Enhancing Physical Performance and Mitigating Acute Mountain Sickness Via Pharmaceutical Intervention While at Altitude Completed NCT01902758 Phase 2, Phase 3 ambrisentan and theophylline;placebo
26 Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Completed NCT01171794 Phase 3 Ibuprofen;Placebo
27 Inhaled Budesonide for Altitude Illness Prevention Withdrawn NCT02941510 Phase 3 Budesonide
28 Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Unknown status NCT01682551 Phase 2 Chinese Medicine;Acetalozamide
29 Prospective, Double-blind, Randomized, Placebo-controlled Trial of Ibuprofen Versus Placebo for Prevention of Neurologic Forms of Altitude Sickness Unknown status NCT01606527 Phase 2 Ibuprofen 600mg orally three times daily
30 Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness. Completed NCT01536288 Phase 2 Rhodiola crenulata;placebo
31 A Double-blind, Randomized and Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of T89 in Prevention and Treatment of Acute Mountain Sickness (AMS) During Rapid Ascent Completed NCT03552263 Phase 2 T89 capsule;Placebo capsule
32 A Randomized, Double Blind, Placebo-controlled Study of Compound Danshen Dripping Pills in Preventing and Treating Acute Mountain Sickness Completed NCT03270787 Phase 1, Phase 2 Placebo;Compound danshen dripping pills
33 A Randomized Controlled Trial of the Effects of Tadalafil and Dexamethasone Versus Placebo on Pulmonary Edema Formation and Cerebral Blood Flow Autoregulation in High Altitude Newcomers With a Previous History of High Altitude Pulmonary Edema Completed NCT00274430 Phase 1, Phase 2 dexamethasone 8 mg bid;tadalafil 10mg bid
34 Randomized Controlled Trial of N-acetylcysteine and Acetazolamide in Treatment of Chronic Mountain Sickness Completed NCT01187108 Phase 1, Phase 2 N-acetylcysteine;Acetazolamide;Placebo pills
35 Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude Unknown status NCT02233582 Phase 1 Ibuprofen
36 Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages Completed NCT03424226 Phase 1 Acetazolamide
37 Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy Completed NCT03154645 Phase 1 Ibuprofen;Acetazolamide
38 Effect of Inhaled Budesonide on the Incidence and Severity of Acute Mountain Sickness at 4559 m Completed NCT02811016 Phase 1 Budesonide 200;Budesonide 800;Placebo
39 Sickness Evaluation at Altitude With Acetazolamide at Relative Doses Completed NCT03828474 Phase 1 Acetazolamide Pill
40 A Randomized, 4-Sequence, Double-Blind Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude Completed NCT01794078 Phase 1 Aminophylline 400 mg;Ambrisentan 5 mg
41 The Safety Evaluation of Aminophylline and Methazolamide When Administered Orally Alone and in Combination to Healthy Volunteers Completed NCT01587027 Phase 1 Aminophylline;Methazolamide;Aminophylline and Methazolamide
42 Hypoxia Impairs Systemic Endothelial Function in Individuals Prone to High-Altitude Pulmonary Edema. Completed NCT00176007 Phase 1
43 A Prospective, Non-Randomized, Open-Label Study on the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children Completed NCT00670891 Phase 1
44 The Safety Evaluation of Theophylline and Bambuterol When Administered Orally Alone and in Combination to Healthy Volunteers Completed NCT01566565 Phase 1 Theophylline and Bambuterol
45 Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE) Suspended NCT03341676 Phase 1 Dexamethasone;Placebo
46 Prevention of Acute Mountain Sickness (AMS) by Intermittent Hypoxic Training Unknown status NCT00886912
47 Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness: A Randomized Controlled Trial Unknown status NCT02972411 Acetazolamide
48 Intolerance Mechanisms and Exercise Performance Limitation During a High Altitude Stay: Investigation of Sleep and Cerebral Responses Unknown status NCT01565603
49 Hemodynamic Changes in Altitude Adaptation Unknown status NCT01698619
50 A Cohort Study of the Effect of High Altitudes on Physiological and Metabolic Markers in Adults Who Live at Qinghai-Tibet Plateau for Work Purpose Unknown status NCT03446898

Search NIH Clinical Center for Acute Mountain Sickness

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Acetazolamide
Acetazolamide sodium

Genetic Tests for Acute Mountain Sickness

Anatomical Context for Acute Mountain Sickness

MalaCards organs/tissues related to Acute Mountain Sickness:

40
Endothelial, Heart, Kidney, Pituitary, Brain, Skeletal Muscle, Smooth Muscle

Publications for Acute Mountain Sickness

Articles related to Acute Mountain Sickness:

(show top 50) (show all 1998)
# Title Authors PMID Year
1
Evaluation of nutrient profile, biochemical composition and anti-gastric ulcer potentialities of khambir, a leavened flat bread. 61
33321345 2021
2
Acute Mountain Sickness, High Altitude Pulmonary Edema, and High Altitude Cerebral Edema: A view from the High Andes. 61
33545376 2021
3
Acute Altitude Acclimatization in Young Healthy Volunteers: Nocturnal Oxygenation Increases Over Time, Whereas Periodic Breathing Persists. 61
33185483 2021
4
[Travelling to High Altitude Destinations after Recovery from COVID-19-infection: New Aspects of Medical Advice in Altitude Medicine]. 61
33152773 2021
5
Altitude-Related Disorders on Mount Kilimanjaro, Tanzania: Two-Year Survey in a Local Referral Center. 61
33431301 2021
6
Extravascular lung water and cardiac function assessed by echocardiography in healthy lowlanders during repeated very high-altitude exposure. 61
33775791 2021
7
Serum neurofilament level increases after ascent to 4559 m but is not related to acute mountain sickness. 61
33095952 2021
8
Altitude, Acute Mountain Sickness, and Acetazolamide: Recommendations for Rapid Ascent. 61
32975448 2021
9
Losartan Has No Effect on High Altitude Diuresis or Acute Mountain Sickness in Well-Acclimatizing Individuals. 61
33783237 2021
10
Efficacy of Acetazolamide for the Prophylaxis of Acute Mountain Sickness: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials. 61
33587912 2021
11
Predictive Capacity of Pulmonary Function Tests for Acute Mountain Sickness. 61
33601996 2021
12
Quercetin: a savior of alveolar barrier integrity under hypoxic microenvironment. 61
33632082 2021
13
High-altitude Illnesses and Air Travel: Pediatric Considerations. 61
33228940 2021
14
Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. 61
33578749 2021
15
Alexander von Humboldt (1769-1859): early high altitude explorer and renowned plant naturalist. 61
33594915 2021
16
The Use of Pulse Oximetry in the Assessment of Acclimatization to High Altitude. 61
33578839 2021
17
Altitude Cardiomyopathy Is Associated With Impaired Stress Electrocardiogram and Increased Circulating Inflammation Makers. 61
33776794 2021
18
Integrative analysis of miRNA-mRNA network in high altitude retinopathy by bioinformatics analysis. 61
33393628 2021
19
The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies. 61
32909898 2021
20
Structural and functional alterations of nitric oxide synthase 3 due to missense variants associate with high-altitude pulmonary edema through dynamic study. 61
31902292 2021
21
High-altitude pulmonary edema. 61
33732460 2021
22
Novel formulation development from Ophiocordyceps sinensis (Berk.) for management of high-altitude maladies. 61
33442508 2021
23
D4F prophylaxis enables redox and energy homeostasis while preventing inflammation during hypoxia exposure. 61
33378979 2021
24
No renal dysfunction or salt and water retention in acute mountain sickness at 4,559 m among young resting males after passive ascent. 61
33180647 2021
25
Changes in prefrontal cerebral oxygenation and microvascular blood volume in hypoxia and possible association with acute mountain sickness. 61
32715540 2021
26
Respiratory alkalinization and posterior cerebral artery dilatation predict acute mountain sickness severity during 10 h normobaric hypoxia. 61
33347666 2021
27
Cardiorespiratory hysteresis during incremental high-altitude ascent-descent quantifies the magnitude of ventilatory acclimatization. 61
32421248 2021
28
Combined methazolamide and theophylline improves oxygen saturation but not exercise performance or altitude illness in acute hypobaric hypoxia. 61
32363610 2021
29
A Randomized Controlled Trial of the Lowest Effective Dose of Acetazolamide for Acute Mountain Sickness Prevention. 61
32479750 2020
30
Re: "The Effect of an Expiratory Resistance Mask With Dead Space on Sleep, Acute Mountain Sickness, Cognition, and Ventilatory Acclimatization in Normobaric Hypoxia," by Patrician et al. and "Global REACH 2018: The Effect of an Expiratory Resistance Mask with Dead Space on Sleep and Acute Mountain Sickness During Acute Exposure to Hypobaric Hypoxia" by Carr et al. 61
32633557 2020
31
Response to Berger et al. re: "Are Pre-Ascent Low-Altitude Saliva Cortisol Levels Related to the Subsequent Acute Mountain Sickness Score? Observations From a Field Study". 61
32552043 2020
32
Deceleration Capacity and Periodic Repolarization Dynamics As Predictors of Acute Mountain Sickness. 61
33147080 2020
33
Response to Millet and Debevec re: "The Effect of an Expiratory Resistance Mask With Dead Space on Sleep, Acute Mountain Sickness, Cognition, and Ventilatory Acclimatization in Normobaric Hypoxia," by Patrician et al. and "Global REACH 2018: The Effect of an Expiratory Resistance Mask with Dead Space on Sleep and Acute Mountain Sickness During Acute Exposure to Hypobaric Hypoxia" by Carr et al. 61
32667827 2020
34
Optic nerve sheath diameter changes at high altitude and in acute mountain sickness: meta-regression analyses. 61
33310776 2020
35
Point-of-Care Ultrasound Diagnosis of Community-Acquired Pneumonia in a High-Altitude, Resource-Poor Setting. 61
33211617 2020
36
[Differential diagnosis of high altitude pulmonary edema and COVID-19 with computed tomography feature]. 61
33369342 2020
37
Evaluation of Serial Chest Radiographs of High-Altitude Pulmonary Edema Requiring Medical Evacuation from South Pole Station, Antarctica: From Diagnosis to Recovery. 61
33269793 2020
38
No Relevant Analogy Between COVID-19 and Acute Mountain Sickness. 61
32970479 2020
39
Morbidity Among Athletes Presenting for Medical Care During 3 Iterations of an Ultratrail Race in the Himalayas. 61
33168403 2020
40
Chinese medicinal plants for the potential management of high-altitude pulmonary oedema and pulmonary hypertension. 61
32883127 2020
41
Improved Neuroimaging Findings and Cognitive Function in a Case of High-altitude Cerebral Edema. 61
33229804 2020
42
Shorter telomere length, higher telomerase activity in association with tankyrase gene polymorphism contribute to high-altitude pulmonary edema. 61
32916703 2020
43
Subclinical elevated B-type Natriuretic Peptide (BNP) indicates endothelial dysfunction contributing to hypoxia susceptibility in healthy individuals. 61
32926931 2020
44
Prophylaxis of ibuprofen in acute mountain sickness: A protocol for systematic review and meta-analysis. 61
33181710 2020
45
Association between physiological responses after exercise at low altitude and acute mountain sickness upon ascent is sex-dependent. 61
33148321 2020
46
Linear and nonlinear analyses of normal and fatigue heart rate variability signals for miners in high-altitude and cold areas. 61
32712570 2020
47
Sleeping with Elevated Upper Body Does Not Attenuate Acute Mountain Sickness: Pragmatic Randomized Clinical Trial. 61
32081656 2020
48
Inhaled budesonide does not prevent acute mountain sickness? 61
33039217 2020
49
Oxygen availability in a HAPE-positive and a HAPE-negative woman before and during a visit to 3480 meters. 61
32745709 2020
50
Vascular homeostasis at high-altitude: role of genetic variants and transcription factors. 61
33282179 2020

Variations for Acute Mountain Sickness

Expression for Acute Mountain Sickness

Search GEO for disease gene expression data for Acute Mountain Sickness.

Pathways for Acute Mountain Sickness

Pathways related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.07 VHL VEGFA HSPA1B HSPA1A HIF1AN HIF1A
2 12.75 VHL VEGFA HIF1A EGLN1 EDN1 BDKRB2
3 12.29 VEGFA NOS3 FLT1 BDKRB2 AGTR1 ADRB2
4
Show member pathways
12.25 VEGFA PIK3C2A NOS3 FLT1
5 11.86 VEGFA NOS3 EDN1 AGTR1
6
Show member pathways
11.77 VHL VEGFA NOS3 HIF1A FLT1
7
Show member pathways
11.75 NOS3 BDKRB2 AGTR1 ACE
8 11.72 NOS3 HIF1AN HIF1A FLT1 EGLN1
9
Show member pathways
11.7 PIK3C2A NOS3 FLT1
10 11.68 EDN1 AGTR1 ADRB2 ACE
11 11.66 VHL VEGFA HIF1A EGLN1
12 11.61 VEGFA HIF1A EGLN1 EDN1
13 11.6 VHL VEGFA NOS3 HIF1A FLT1 ENO2
14
Show member pathways
11.53 NOS3 HSPA1B HSPA1A
15
Show member pathways
11.22 VEGFA HIF1A EDN1
16 11.22 VEGFA HIF1AN HIF1A EGLN1 EDN1
17 11.09 VHL VEGFA HIF1AN FLT1 EGLN1
18 11.01 VHL VEGFA NOS3 HSPA1B HSPA1A HIF1AN
19 11 VEGFA NOS3 HIF1A FLT1
20 10.86 VHL HIF1AN HIF1A
21 10.59 VEGFA HIF1AN HIF1A
22 10.49 NOS3 MB

GO Terms for Acute Mountain Sickness

Cellular components related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.47 VHL VEGFA S100B PIK3C2A NOS3 HSPA1B

Biological processes related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.04 VEGFA S100B FLT1 EDN1 CCK
2 negative regulation of apoptotic process GO:0043066 10.04 VHL VEGFA HSPA1B HSPA1A HIF1A
3 positive regulation of gene expression GO:0010628 10.03 VEGFA NOS3 HSPA1B HSPA1A HIF1A
4 response to hypoxia GO:0001666 9.84 VEGFA HIF1A EGLN1 EDN1
5 negative regulation of gene expression GO:0010629 9.83 VHL VEGFA HIF1A EDN1 ACE
6 regulation of blood pressure GO:0008217 9.78 NOS3 EDN1 ACE
7 positive regulation of angiogenesis GO:0045766 9.78 VEGFA NOS3 HIF1A FLT1
8 positive regulation of MAP kinase activity GO:0043406 9.77 VEGFA FLT1 EDN1
9 cellular response to hypoxia GO:0071456 9.71 VEGFA HIF1A EGLN1 EDN1
10 positive regulation of blood vessel endothelial cell migration GO:0043536 9.7 VEGFA NOS3 HIF1A
11 positive regulation of signaling receptor activity GO:2000273 9.63 HIF1A EDN1
12 positive regulation of tumor necrosis factor-mediated signaling pathway GO:1903265 9.62 HSPA1B HSPA1A
13 negative regulation of inclusion body assembly GO:0090084 9.62 HSPA1B HSPA1A
14 regulation of cell death GO:0010941 9.61 HSPA1B HSPA1A
15 oxygen homeostasis GO:0032364 9.6 HIF1A EGLN1
16 positive regulation of microtubule nucleation GO:0090063 9.58 HSPA1B HSPA1A
17 cellular heat acclimation GO:0070370 9.58 HSPA1B HSPA1A
18 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.57 VEGFA HIF1A
19 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.56 NOS3 EDN1
20 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.55 AGTR1 ACE
21 positive regulation of erythrocyte differentiation GO:0045648 9.54 HSPA1B HSPA1A HIF1A
22 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.51 VEGFA ACE
23 blood vessel morphogenesis GO:0048514 9.5 HIF1A FLT1 EDN1
24 positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070434 9.49 HSPA1B HSPA1A
25 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.46 VHL HIF1AN
26 regulation of blood vessel diameter GO:0097746 9.46 NOS3 AGTR1 ADRB2 ACE
27 positive regulation of chemokine-mediated signaling pathway GO:0070101 9.26 HIF1A EDN1
28 regulation of vasoconstriction GO:0019229 9.26 EDN1 BDKRB2 AGTR1 ACE
29 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.02 VHL VEGFA HIF1AN HIF1A EGLN1

Molecular functions related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 C3HC4-type RING finger domain binding GO:0055131 9.16 HSPA1B HSPA1A
2 enzyme binding GO:0019899 9.1 VHL HSPA1B HSPA1A HIF1A EGLN1 ADRB2
3 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE

Sources for Acute Mountain Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....